PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced: MDSC-mediated T cell activation
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Tumor-infiltrating myeloid cells such as myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) form an important component of the hypoxic tumor microenvironment. Here, we investigated the influence of hypoxia on immune checkpoint receptors (programmed death [PD]-1 and CTLA-4) and their respective ligands (PD-1 ligand 1 [PD-L1], PD-L2, CD80, and CD86) on MDSCs. We demonstrate that MDSCs at the tumor site show a differential expression of PD-L1 as compared with MDSCs from peripheral lymphoid organ (spleen). Hypoxia caused a rapid, dramatic, and selective up-regulation of PD-L1 on splenic MDSCs in tumor-bearing mice. This was not limited to MDSCs, as hypoxia also significantly increased the expression of PD-L1 on macrophages, dendritic cells, and tumor cells. Furthermore, PD-L1 up-regulation under hypoxia was dependent on hypoxia-inducible factor-1α (HIF-1α) but not HIF-2α. Chromatin immunoprecipitation and luciferase reporter assay revealed direct binding of HIF-1α to a transcriptionally active hypoxia-response element (HRE) in the PD-L1 proximal promoter. Blockade of PD-L1 under hypoxia enhanced MDSC-mediated T cell activation and was accompanied by the down-regulation of MDSCs IL-6 and IL-10. Finally, neutralizing antibodies against IL-10 under hypoxia significantly abrogated the suppressive activity of MDSCs. Simultaneous blockade of PD-L1 along with inhibition of HIF-1α may thus represent a novel approach for cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4. Blockade of PD-L1 under hypoxia down-regulates MDSC IL-6 and IL-10 and enhances T cell proliferation and function. MDSCs isolated from spleens of B16-F10 tumor-bearing mice were pretreated for 30 min on ice with 5 µg/ml control antibody (IgG) or antibody against PD-L1 (PDL1 Block) and co-cultured with splenocytes under normoxia and hypoxia for 72 h. (A and B) Effect of MDSC on proliferation of splenocytes stimulated with (A) anti-CD3/CD28 coated beads or (B) TRP-2(180–88) peptide under the indicated conditions. Cell proliferation was measured in triplicates by [3H]thymidine incorporation and expressed as counts per minute (CPM). (C and D) MDSCs were cultured with splenocytes from B16-F10 mice stimulated with anti-CD3/CD28. Intracellular IFN-γ production was evaluated by flow cytometry by gating on (C) CD3+CD8+ IFN-γ+ and (D) CD3+CD4+ IFN-γ+ populations. Statistically significant differences (indicated by asterisks) are shown (**, P < 0.005; ***, P < 0.0005). Three separate experiments (in triplicates) with the same results were performed. Error bars indicate SD. (E) SYBR-GREEN RT-qPCR was performed to evaluate the mRNA expression levels of Ldha, Car-9, Arg-1, Nos2, Ncf-1, and Cybb-1. (F) Arginase enzymatic activity measured in MDSCs under indicated conditions. (G) After 72 h of MDSC co-culture with splenocytes, supernatants were collected and assayed for nitrites. Data represents three independent experiments with SD. (H) SYBR Green RT-qPCR was performed for expression levels of IL6, IL10, Il12p70, and Tgfb1 under the indicated conditions. IL-6, IL-10, IL-12p70, and TGF-β1 cytokine production and secretion was detected by (I and J) intracellular FACS staining (isotype control is gray-shaded histogram) and (K) ELISA, respectively. Statistically significant differences (indicated by asterisks) are shown (*, P < 0.05; **, P < 0.005; ***, P < 0.0005). The experiment was performed in triplicates and repeated three times with the same results. Error bars indicate SD. (L–O) MDSCs isolated from spleens of B16-F10 tumor-bearing mice were co-cultured with splenocytes under normoxia and hypoxia for 72 h in the presence of either 10 µg/ml control antibody (IgG), anti–mouse IL-6 Functional Grade Purified neutralizing antibody (IL-6 Block) or anti–mouse IL-10 Functional Grade Purified neutralizing antibody (IL-10 Block). Effect of MDSCs on proliferation of splenocytes stimulated with (L) anti-CD3/CD28–coated beads or (M) TRP-2(180–88) peptide under the indicated conditions. Cell proliferation was measured as indicated above. MDSCs were cultured with splenocytes from B16-F10 mice stimulated with anti-CD3/CD28. Intracellular IFN-γ production was evaluated by flow cytometry by gating on (N) CD3+CD8+ IFN-γ+ and (O) CD3+CD4+ IFN-γ+ populations. Statistically significant differences (indicated by asterisks) are shown (*, P < 0.05; **, P < 0.005). Two separate experiments (in triplicates) with the same results were performed. Error bars indicate SD.](https://figures.cochat.ai/paper-figures/2ba8a156b22c410c8802e99a6f19ff08/pd-l1-is-a-novel-direct-target-of-hif-1-and-its-blockade-under-hypoxia-enhanced-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Intriguingly, HIF-1α, but not HIF-2α, directly upregulates the expression of PD-L1 in macrophages, dendritic cells and bone marrow derived macrophages (BMDMs), by binding HREs within the PD-L1 promoter (Fig. 2C) [68–70].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [68]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As seen for the other cancer axes, the HIF-α dependency of PD-L1 is tumor-type dependent, with PD-L1 expression primarily HIF-1α driven in HIF-1α-dominant cancers (such as CT26 colon carcinoma and 4T1 breast carcinoma models) and HIF-2α-driven in HIF-2α-dominant cancers (ccRCC) [81, 83].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to regulating components of the innate immune response, the HIFs have been linked to modulation of the adaptive immune response through upregulation of both co-inhibitory (eg. PD-L1 and CTLA4) and co-stimulatory receptors (eg. 4–1BB, OX40) on activated T cells [80, 81].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent data indicate that hypoxia is also able to upregulate expression of PD-L1 in malignant cells via HIF-1α and HIF-2α (17).”
From Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy (2022) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Targeting HIF-1α in immunotherapy is a relatively new concept, for which proof of principle has been amply demonstrated by others (12, 23, 27).”
From Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues (2022) · cites this paper as [12]
Experimental — accuracy not yet measured
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“A large body of preclinical and clinical data indicates that antibody blockade of immune checkpoints can significantly enhance antitumor immunity (Pardoll, 2012; West et al., 2013).”
BackgroundSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 2×
“, 2012) and its ligand, PD-L1 (Brahmer et al., 2012), was shown to result in durable tumor regression and prolonged stabilization of disease in patients with advanced cancers.”
BackgroundCoordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 1×
“MDSCs are a heterogeneous group of relatively immature myeloid cells and several studies have described mechanisms of MDSCmediated immune suppression (Gabrilovich et al., 2012).”
BackgroundSelf-citationGreenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318 · cited 1×
“PD-1, a cell surface glycoprotein with a structure similar to cytotoxic T lymphocyte antigen 4 (CTLA-4), belongs to the B7 family of co-stimulatory/co-inhibitory molecules and plays a key part in immune regulation (Greenwald et al., 2005).”
BackgroundSubsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J.-I., Nagaraj, S., Collazo, M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645 · cited 3×
“It is important to underline that our results are in complete agreement with previous findings by Youn et al. (2008), indicating that normoxic blockade of PD-L1 did not eliminate suppressive activity of MDSCs.”
BackgroundMethodResultInfluentialBlockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314 · cited 12×
“2 I) and DCs (CD11c+; Fig.”
BackgroundResultInfluentialPD-1 and PD-1 ligands: from discovery to clinical application
Okazaki, T., & Honjo, T. (2007) · International Immunology · doi:10.1093/intimm/dxm057 · Cited by 1,310
Corzo, C. A., Condamine, T., Lu, L., Cotter, M. J., Youn, J.-I., Cheng, P., Cho, H.-I., Celis, E., Quiceno, D. G., Padhya, T., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100587 · Cited by 1,173 · cited 6×
“As shown previously by Corzo et al. (2010), we observed higher levels of Arg-1 gene expression (Fig.”
BackgroundInfluentialOxygen Sensing, Homeostasis, and Disease
Semenza, G. L. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011165 · Cited by 993 · cited 1×
“2014 Vol. 211 No. 5 781-790 www.jem.org/cgi/doi/10.1084/jem.20131916 781 Brief Definit ive Report Hypoxia is a common feature of solid tumors (Semenza, 2011).”
BackgroundInfluential
Cited by
Items 901–1,000 of 1,009
Mennitto, A., Huber, V., Ratta, R., Sepe, P., de Braud, F., Procopio, G., Guadalupi, V., Claps, M., Stellato, M., Daveri, E., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040930 · Cited by 37
“Considering instead drug sequences, the administration of ICIs at the failure of antiangiogenics could be penalized by the accrual of immunosuppressive cells such as MDSCs, which associate with resistance to the VEGF blockade and an immune hostile milieu always paralleling progressing cancers [86,87].”
BackgroundInfluentialKhandani, N. K., Ghahremanloo, A., & Hashemy, S. I. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29671 · Cited by 41
“…the increased HIF‐1 levels in hypoxic conditions causing the downregulation of T‐cell activity and induction of PD‐L1 on the surface of tumor cells, resulting in immune suppression and increased cell proliferation of tumor cells (Koh et al., 2019; Noman et al., 2014; M. Z. Zou et al., 2018).”
BackgroundPD-L1+ exosomes from bone marrow-derived cells of tumor-bearing mice inhibit antitumor immunity
Sun, Y., Guo, J., Yu, L., Guo, T., Wang, J., Wang, X., & Chen, Y. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0487-7 · Cited by 35
Tittarelli, A., Navarrete, M., Lizana, M., Hofmann-Vega, F., & Salazar‐Onfray, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207567 · Cited by 36
“For example, it has been shown that hypoxia increases the expression of the immune checkpoint programmed death-ligand 1 (PD-L1) on melanoma cells and tumor infiltrating immune cells, via the transcriptional activity of hypoxia-inducible factor-1α (HIF-1α), leading to lower levels of CTL activation and tumor eliminatio…”
BackgroundHypoxia-inducible factor 1 alpha limits dendritic cell stimulation of CD8 T cell immunity
Tran, C. W., Gold, M. J., Garcia-Batres, C. R., Tai, K., Elford, A. R., Himmel, M. E., Elia, A., & Ohashi, P. S. (2020) · PLoS ONE · doi:10.1371/journal.pone.0244366 · Cited by 40
“The expression levels of other markers such as CD103, OX40L, CCR7 or inhibitory molecules including PD-L1 (a predicted HIF-1α target [26]) and PD-L2, were also found to be similar between WT and HIF-1α-Tg BMDCs (Fig 1G).”
ResultLost in application: Measuring hypoxia for radiotherapy optimisation
Thiruthaneeswaran, N., Bibby, B. A. S., Yang, L., Hoskin, P., Bristow, R. G., Choudhury, A., & West, C. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.039 · Cited by 37
Study on hypoxia-inducible factor and its roles in immune system
Kiani, A. A., Elyasi, H., Ghoreyshi, S., Nouri, N., Safarzadeh, A., & Nafari, A. (2021) · Immunological Medicine · doi:10.1080/25785826.2021.1910187 · Cited by 43
Li, X., Li, Y., Yu, Q., Qian, P., Huang, H., & Lin, Y. (2021) · Journal of Leukocyte Biology · doi:10.1002/jlb.1mr0421-597rr · Cited by 41
The role of PD-L1 in the immune dysfunction that mediates hypoxia-induced multiple organ injury
Sun, Y., Tan, J., Miao, Y., & Zhang, Q. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-021-00742-x · Cited by 40
“the transcription factors HIF‐1α and NF‐κB Transcriptional factors, such as HIF-1α, and nuclear factor-κB (NF-κB), can regulate PD-L1 expression through targeting its promoter region [30].”
BackgroundInfluentialImmunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Hsieh, R. W., Borson, S., Tsagianni, A., & Zandberg, D. P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.705614 · Cited by 43
Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?
Kuske, M., Haist, M., Jung, T., Grabbe, S., & Bros, M. (2022) · Cancers · doi:10.3390/cancers14071710 · Cited by 39
Zhang, M., Wang, L., Liu, W., Wang, T., Sanctis, F. D., Lifang, Z., Zhang, G., Cheng, J. G., Cao, Q., Zhou, J., et al. (2022) · Journal of Immunology Research · doi:10.1155/2022/2253436 · Cited by 42
Self-citationMyeloid-derived suppressor cells in lymphoma: The good, the bad and the ugly
Betsch, A., Rutgeerts, O., Fevery, S., Sprangers, B., Verhoef, G. E. G., Dierickx, D., & Beckers, M. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.04.006 · Cited by 36
Deng, C., Deng, G., Chu, H., Chen, S., Chen, X., Li, X., He, Y., Sun, C., & Zhang, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1140328 · Cited by 38
“Hypoxia significantly upregulates PD-L1 expression in immune cells in a HIF-1a-dependent manner (36).”
BackgroundMa, X., Zhou, X. M., Hu, B., Li, X., Yao, M., Li, L., Qin, X., Li, D., Yao, Y., Hou, X., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06373-3 · Cited by 37
Immunoantitumor Activity and Oxygenation Effect Based on Iron–Copper-Doped Folic Acid Carbon Dots
Li, S., Zhang, H., Bao, Y., Zhang, H., Wang, J., Liu, M., Yan, R., Wang, Z., Wu, X., & Jin, Y. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c18331 · Cited by 38
Lynce, F. C., Mainor, C. B., Donahue, R. N., Geng, X., Jones, G., Schlam, I. M., Wang, H., Toney, N. J., Jochéms, C., Schlom, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46961-x · Cited by 39
Immune Cell Migration to Cancer
Ryan, A. T., Kim, M., & Lim, K. (2024) · Cells · doi:10.3390/cells13100844 · Cited by 38
Exploring immune checkpoint inhibitors: Focus on PD-1/PD-L1 axis and beyond
Aden, D., Zaheer, S., Sureka, N., Trisal, M., Chaurasia, J. K., & Zaheer, S. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.155864 · Cited by 41
Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy
Farsaci, B., Donahue, R. N., Grenga, I., Lepone, L. M., Kim, P. S., Dempsey, B. E., Siebert, J., Ibrahim, N. K., Madan, R. A., Heery, C. R., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0037 · Cited by 37
“% CD8 Positive % Central memory CD8 Positive (19) % CD8 expressing 2 suppressive markers Negative (20, 21) % Treg Negative % Treg ICOSþ Negative (28) % cDC PD-L1þ Negative (30) % MDSC Negative % MDSC PD-L1þ Negative (31, 32) % NK Positive % NK TIM3 Negative (29)”
BackgroundThe Impact of Smoking on Sentinel Node Metastasis of Primary Cutaneous Melanoma
Jones, M. S., Jones, P. C., Stern, S. L., Elashoff, D. A., Hoon, D. S. �., Thompson, J. F., Mozzillo, N., Nieweg, O. E., Noyes, D. R., Hoekstra, H. J., et al. (2017) · Annals of Surgical Oncology · doi:10.1245/s10434-017-5775-9 · Cited by 34
Perdrizet, K., & Leighl, N. B. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0617-6 · Cited by 37
JQ1, a BET‐bromodomain inhibitor, inhibits human cancer growth and suppresses PD‐L1 expression
Liu, K., Zhou, Z., Gao, H., Yang, F., Qian, Y., Jin, H., Guo, Y., Liu, Y., Li, H., Zhang, C., et al. (2019) · Cell Biology International · doi:10.1002/cbin.11139 · Cited by 36
Yamaguchi, O., Kaira, K., Hashimoto, K., Mouri, A., Shiono, A., Miura, Y., Murayama, Y., Kobayashi, K., Kagamu, H., & Kuji, I. (2020) · Scientific Reports · doi:10.1038/s41598-020-71735-y · Cited by 39
Shou, Y., Yang, L., Yang, Y., Zhu, X., Feng, L., & Xu, J. (2021) · Molecular Omics · doi:10.1039/d0mo00159g · Cited by 35
Zhao, S., Gao, J., Li, J., Wang, S., Yuan, C., & Liu, Q. (2021) · Inflammation · doi:10.1007/s10753-021-01474-3 · Cited by 36
“HIF-1α directly binds to the hypoxic response element in the proximal promoter of PDL1, thereby regulating its transcription [39].”
BackgroundGao, Y., Sun, Z., Gu, J., Li, Z., Xu, X., Xue, C., Li, X., Zhao, L., Zhou, J., Bai, C., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.748465 · Cited by 42
“It has been found that hypoxia−inducible factor−1 (HIF-1) could bind with hypoxic response element (HRE) and upregulate the PD-L1 expression, simultaneously cause T-cell apoptosis and function inhibition (48, 49).”
BackgroundThe Role of Imaging Biomarkers to Guide Pharmacological Interventions Targeting Tumor Hypoxia
Gallez, B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.853568 · Cited by 37
Han, J., Dong, L., Wu, M., & Ma, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1160340 · Cited by 39
Ianni, N. D., Musio, S., & Pellegatta, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094460 · Cited by 36
“hypoxia via HIF1α upregulates the programmed cell death ligand PD-L1 on MDSCs, a modulation crucial for T cell suppression activity [65].”
BackgroundHill, R. M., Rocha, S., & Parsons, J. L. (2022) · Cancers · doi:10.3390/cancers14174130 · Cited by 41
Logghe, T., van Zwol, E., Immordino, B., den Cruys, K. V., Peeters, M., Giovannetti, E., & Bogers, J. (2024) · Cancers · doi:10.3390/cancers16030505 · Cited by 42
Jou, E., Chaudhury, N., & Nasim, F. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00212 · Cited by 43
MDSC: a new potential breakthrough in CAR-T therapy for solid tumors
Abdalsalam, N. M. F., Ibrahim, A., Saliu, M. A., Liu, T., Wan, X., & Yan, D. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01995-y · Cited by 41
Lactate-induced protein lactylation in cancer: functions, biomarkers and immunotherapy strategies
Wang, W., Wang, H., Wang, Q., Yu, X., & Ouyang, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1513047 · Cited by 36
Harnessing myeloid cells in cancer
Park, S., Pylaeva, E., Bhuria, V., Gambardella, A. R., Schiavoni, G., Mougiakakos, D., Kim, S.-H., & Jabłońska, J. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02249-2 · Cited by 40
“Tumor-supportive neutrophils suppress both innate and adaptive immunity through various mechanisms, including the secretion of ROS [150], and immunosuppressive cytokines such as IL-10 and TGF-β [151, 152], and contact-dependent suppression via PD-L1 [153].”
Next Generation Cancer Vaccines—Make It Personal!
Terbuch, A., & Lopez, J. S. (2018) · Vaccines · doi:10.3390/vaccines6030052 · Cited by 37
“Cancer associated hypoxia increases the expression of PD-L1 on MDSCs via induction of hypoxia-inducible factor 1-α [8].”
BackgroundAdult immuno-oncology: using past failures to inform the future
Rahman, M., Sawyer, W. G., Lindhorst, S., Deleyrolle, L. P., Harrison, J. K., Karachi, A., Dastmalchi, F., Flores‐Toro, J., Mitchell, D. A., Lim, M. K., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa116 · Cited by 43
Escape of tumor cells from the NK cell cytotoxic activity
Cantoni, C., Wurzer, H., Thomas, C., & Vitale, M. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.2mr0820-652r · Cited by 42
Messeha, S. S., Zarmouh, N. O., & Soliman, K. F. A. (2021) · Nutrients · doi:10.3390/nu13051718 · Cited by 37
Cao, R., Ma, B., Wang, G., Xiong, Y., Tian, Y., & Yuan, L. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.06.011 · Cited by 37
Immunometabolism modulation, a new trick of edible and medicinal plants in cancer treatment
Tan, W., Pan, T., Wang, S., Li, P., Men, Y., Tan, R., Zhong, Z., & Wang, Y. (2021) · Food Chemistry · doi:10.1016/j.foodchem.2021.131860 · Cited by 39
Natural Killer Cells in the Malignant Niche of Multiple Myeloma
Venglár, O., Bago, J., Motais, B., Hájek, R., & Jelínek, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.816499 · Cited by 36
HSP90 Mediates IFNγ-Induced Adaptive Resistance to Anti-PD-1 Immunotherapy
Liu, K., Huang, J., Liu, J., Li, C., Kroemer, G., Tang, D., & Kang, R. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3917 · Cited by 38
Neoadjuvant therapy alters the immune microenvironment in pancreatic cancer
Zhang, H., Ye, L., Yu, X., Jin, K., & Wu, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.956984 · Cited by 39
Multifaceted Interplay between Hormones, Growth Factors and Hypoxia in the Tumor Microenvironment
Lappano, R., Todd, L. A., Stanic, M., Cai, Q., Maggiolini, M., Marincola, F., & Pietrobon, V. (2022) · Cancers · doi:10.3390/cancers14030539 · Cited by 32
The clinical and immune features of CD14 in colorectal cancer identified via large-scale analysis
Chen, D., & Wang, H. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106966 · Cited by 37
Repression of the stress granule protein G3BP2 inhibits immune checkpoint molecule PD‐L1
Zhang, Y., Yue, C., Krichevsky, A. M., & Garkavtsev, I. (2021) · Molecular Oncology · doi:10.1002/1878-0261.12915 · Cited by 37
Zheng, H., Wang, G., Liu, M., & Cheng, H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1168226 · Cited by 39
Hypoxia-Induced Signaling in Gut and Liver Pathobiology
Solanki, S. A., & Shah, Y. M. (2023) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-051122-094743 · Cited by 38
Yu, P., Wang, Y., Yuan, D., Sun, Y., Qin, S., & Li, T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1276694 · Cited by 37
Hypoxia-induced ZEB1 promotes cervical cancer immune evasion by strengthening the CD47-SIRPα axis
Chen, X., Guo, C.-H., Wang, Z., Yang, Y., Pan, Y.-H., Liang, J.-Y., Sun, M.-G., Fan, L., Li, L., & Wang, W. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01450-4 · Cited by 37
“The hypoxia-inducing factors HIF-1α and HIF-2α can regulate the expression of immune checkpoints such as PD-L1 [9].”
BackgroundMoeller, M., Orth, V., Umansky, V., Hetjens, S., Braun, V., Reißfelder, C., Hardt, J., & Seyfried, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1403771 · Cited by 37
Fu, Y., Guo, X., Sun, L., Cui, T., Wu, C., Wang, J., Liu, Y., & Liu, L. (2024) · eLife · doi:10.7554/elife.95009 · Cited by 39
“…other immune checkpoint molecules like VISTA, Gal-9, and CD155 have been implicated in MDSC-mediated immunosuppression ( Wu et al., 2019b ; Johnston et al., 2014 ; Zhang et al., 2020 ; Limagne et al., 2019 ; Le Mercier et al., 2014 ; Wang et al., 2018 ; Noman et al., 2014 ; Antonios et al., 2017 ).”
BackgroundSynthetic Promoters in Gene Therapy: Design Approaches, Features and Applications
Artemyev, V., Gubaeva, A., Paremskaia, A. I., Dzhioeva, A. A., Deviatkin, A. A., Feoktistova, S. G., Mityaeva, O. N., & Volchkov, P. (2024) · Cells · doi:10.3390/cells13231963 · Cited by 43
“This method of promoter analysis can be performed in vitro using cell cultures instead of animals [132], as this technique was originally developed [133].”
Hu, T., Zhai, J., Yang, Z., Peng, J., Wang, C., Liu, X., Li, Y., Yao, J., Chen, F., Li, H., et al. (2025) · MedComm · doi:10.1002/mco2.70231 · Cited by 40
“…upregulation of PD-L1 on splenic MDSCs in tumor-bearing mice, and this upregulation depends on hypoxia-inducible factor-1 α (HIF-1 α ), which regulates PD-L1 expression by directly binding to the transcriptionally active hypoxia-responsive element in the proximal promoter of PD-L1 [104, 105].”
Wu, C., Xu, T., Zhang, H., Hu, Y., Jiao, J., Qiu, K. L., Gu, J. L., Li, W., & Sun, L. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217913 · Cited by 39
Noman, M. Z., Janji, B., Berchem, G., & Chouaïb, S. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.10.026 · Cited by 36
Self-citationResistance to anticancer immunity in cancer patients: potential strategies to reverse resistance
Bonavida, B., & Chouaïb, S. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw615 · Cited by 33
Leiber, A., Schwarz, J., Köstlin, N., Spring, B., Fehrenbach, B., Katava, N., Poets, C. F., & Gille, C. (2017) · European Journal of Immunology · doi:10.1002/eji.201646621 · Cited by 33
Immune Cell Metabolism in Tumor Microenvironment
Li, Y., Wan, Y. Y., & Zhu, B. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-94-024-1170-6_5 · Cited by 37
Filippova, N., Yang, X., An, Z., Nabors, B., & Pereboeva, L. (2018) · Journal of Cancer Science & Therapy · doi:10.4172/1948-5956.1000543 · Cited by 35
“Potential HIF1A binding sites have been found in the PDL1 proximal promoter and the intron regions between the first and second, and the fourth and fifth exons of the PDL1 gene [23,24].”
BackgroundFacing the future: challenges and opportunities in adoptive T cell therapy in cancer
Magalhaes, I., Carvalho‐Queiroz, C., Hartana, C. A., Kaiser, A. M., Lukic, A., Mints, M., Nilsson, O., Grönlund, H., Mattsson, J., & Berglund, S. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1608179 · Cited by 32
“The hypoxia resulting from vessel compression and high interstitial pressure in itself suppresses the cytotoxic effects of T and NK cells; recruits myeloid-derived suppressor cells (MDSCs) [118], Tregs, and TAMs [119]; and stimulates programmed death-ligand 1(PD-L1) expression [120].”
BackgroundRole of myeloid-derived suppressor cells in immune checkpoint inhibitor therapy in cancer
Park, S.-M., & Youn, J. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01165-6 · Cited by 34
Gebhardt, C., Simon, S. C. S., Weber, R., Gries, M., Mun, D. H., Reinhard, R. R., Holland‐Letz, T., Umansky, V., & Utikal, J. S. (2020) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104274 · Cited by 34
Targeting myeloid-derived suppressor cells for cancer therapy
Tang, H., Li, H., & Sun, Z. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0806 · Cited by 38
The Role of Oncogenes and Redox Signaling in the Regulation of PD-L1 in Cancer
Glorieux, C., Xia, X., & Huang, P. (2021) · Cancers · doi:10.3390/cancers13174426 · Cited by 37
Therapy-induced shaping of the glioblastoma microenvironment: Macrophages at play
Erbani, J. M., Boon, M., & Akkari, L. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.05.003 · Cited by 37
Sipe, L. M., Chaib, M., Korba, E. B., Jo, H., Lovely, M. C., Counts, B. R., Tanveer, U. A., Holt, J. R., Clements, J. C., John, N. A., et al. (2022) · eLife · doi:10.7554/elife.79143 · Cited by 34
Gallazzi, M., Ucciero, M. A. M., Faraci, D., Mahmoud, A. M., Essa, W. A., Gaïdano, G., Mouhssine, S., & Crisà, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147542 · Cited by 35
“Engagement of PD-1 with its ligand PD-L1 (or CD274), expressed on the surface of tumor cells and MDSCs, leads to the attenuation of TCR-mediated signaling [54,55].”
BackgroundBonet‐Aleta, J., Calzada-Funes, J., & Hueso, J. L. (2022) · Applied Materials Today · doi:10.1016/j.apmt.2022.101628 · Cited by 41
Wang, J. C. C., & Sun, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105837 · Cited by 33
“In addition to IFNΓ, IL-10, VEGF, and hypoxia are other novel critical modulators of PD-L1 expression in MDSCs [63,64].”
BackgroundDong, M., Zhang, X., Peng, P., Chen, Z., Zhang, Y., Wan, L., Wang, X., Liu, G., Guo, Y., Xiao, Q., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216801 · Cited by 33
Zhang, T., Lv, Q., & Jin, W. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189137 · Cited by 44
Kajiwara, T., Tanaka, T., Kukita, K., Kutomi, G., Saito, K., Okuya, K., Takaya, A., Kochin, V., Kanaseki, T., Tsukahara, T., et al. (2016) · European Journal of Immunology · doi:10.1002/eji.201646525 · Cited by 32
Köstlin, N., Schoetensack, C., Schwarz, J., Spring, B., Marmé, A., Goelz, R., Brodbeck, G., Poets, C. F., & Gille, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01098 · Cited by 31
Agrawal, N., Streață, I., Pei, G., Weiner, J. M., Kotzé, L. A., Bandermann, S., Lozza, L., Walzl, G., du Plessis, N., Ioana, M. I., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02417 · Cited by 36
Functional Diversity of Myeloid-Derived Suppressor Cells: The Multitasking Hydra of Cancer
Jayakumar, A., & Bothwell, A. L. M. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900500 · Cited by 32
“Although blockade of PD-L1 reversed T cell suppression by MDSCs under hypoxic conditions (35), PD-L1 on in vitro–generated MDSCs or MDSCs from EL-4 tumor-bearing mice did not suppress T cells (22, 36).”
BackgroundWen, Q.-X., Han, T., Wang, Z., & Jiang, S. (2020) · Oncology Letters · doi:10.3892/ol.2020.11369 · Cited by 44
“Furthermore, the inhibition of PD‐L1 expression significantly decreased the secretion of IL-6 and IL-10 by MDSC, leading to the activation of T cells (22).”
BackgroundMetabolic programming of tumor associated macrophages in the context of cancer treatment
Crezee, T., Rabold, K., de Jong, L., Jaeger, M., & Netea-Maier, R. T. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-1114 · Cited by 33
“HIF-1α and interferon gamma (IFN-γ) signaling in the TME induces the expression of PD-L1 in TAMs, suppressing antitumor immunity (117).”
BackgroundPD-1 immunobiology in glomerulonephritis and renal cell carcinoma
Curran, C. S., & Kopp, J. B. (2021) · BMC Nephrology · doi:10.1186/s12882-021-02257-6 · Cited by 33
“Immunotherapy patient TECs [9] PD-L1 Kidney biopsies from anti-PD-1 immunotherapy patients that developed acute interstitial nephritis exhibit elevated TEC PD-L1 staining compared to those with acute tubular necrosis Glomerulonephritis macrophages [55] PD-L1 The lupus-prone NZM mouse strain +/- antiglomerular basement…”
BackgroundInfluentialHot or cold: Bioengineering immune contextures into in vitro patient-derived tumor models
Too, N. S. H., Ho, N. C. W., Adine, C., Iyer, N. G., & Fong, E. L. S. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.001 · Cited by 34
Research progress of tumor targeted drug delivery based on PD-1/PD-L1
Liu, D., Gao, S., Zhai, Y., Yang, X., & Zhai, G. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121527 · Cited by 30
Ghorbaninezhad, F., Asadzadeh, Z., Masoumi, J., Mokhtarzadeh, A., Kazemi, T., Maleki, L. A., Shotorbani, S. S., Shadbad, M. A., Baghbanzadeh, A., Hemmat, N., et al. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120466 · Cited by 39
Beyond adjuvants: Immunomodulation strategies to enhance T cell immunity
Kamphorst, A. O., Araki, K., & Ahmed, R. (2015) · Vaccine · doi:10.1016/j.vaccine.2014.12.082 · Cited by 34
Small Molecule Targeting Immune Cells: A Novel Approach for Cancer Treatment
Singh, S., Barik, D., Arukha, A. P., Prasad, S., Mohapatra, I., Singh, A. R., & Singh, G. (2023) · Biomedicines · doi:10.3390/biomedicines11102621 · Cited by 34
“Similarly, MDSCs in the tumor-bearing hosts release immunosuppressive cytokine TGF-β [132].”
BackgroundTzeng, A., Diaz-Montero, C. M., Rayman, P. A., Kim, J. S., Pavicic, P. G., Finke, J. H., Barata, P. C., Lamenza, M., Devonshire, S., Schach, K., et al. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0595-9 · Cited by 30
Stresses in the metastatic cascade: molecular mechanisms and therapeutic opportunities
Shen, M., & Kang, Y. (2020) · Genes & Development · doi:10.1101/gad.343251.120 · Cited by 33
Zeng, D., Wang, M., Wu, J., Lin, S., Ye, Z., Zhou, R., Wang, G., Wu, J., Sun, H., Bin, J., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.620688 · Cited by 34
Implications of genetic heterogeneity in hepatocellular cancer
Suresh, A., & Dhanasekaran, R. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2022.01.007 · Cited by 38
Hypoxia, a Targetable Culprit to Counter Pancreatic Cancer Resistance to Therapy
Khouzam, R. A., Lehn, J., Mayr, H., Clavien, P., Wallace, M. B., Ducreux, M. P., Limani, P., & Chouaïb, S. (2023) · Cancers · doi:10.3390/cancers15041235 · Cited by 39
“We have shown that hypoxia induced miR210 [40] and Tregs [36], and was able to activate myeloid-derived suppressor cells (MDSC) by inducing PD-L1 expression by these cells [41].”
BackgroundCui, Z., Ruan, Z., Li, M., Ren, R., Ma, Y., Zeng, J., Sun, J., Ye, W., Xu, W., Guo, X., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110652 · Cited by 30
Luo, H., Wang, Q., Yang, F., Liu, R. R., Gao, Q., Cheng, B., Lin, X., Huang, L., Chen, C., Jin, X., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.164968 · Cited by 220
TRAF6 enhances PD-L1 expression through YAP1-TFCP2 signaling in melanoma
Wang, L., Liu, X., Han, Y., Tsai, H., Dan, Z., Yang, P., Xu, Z., Shu, F., He, C., Eriksson, J., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216861 · Cited by 43
Hypoxic tumor microenvironment: Destroyer of natural killer cell function
Zhang, Y., Guo, F., & Wang, Y. (2024) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2024.02.04 · Cited by 36
Nanozyme-based cancer theranostics: A scientometric analysis and comprehensive review
Yang, X., Yasinjan, F., Sun, S., Yang, J., Du, Y., Zhang, H., Liang, Y., Geng, H., Wang, Y., Sun, J., et al. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102386 · Cited by 31
Li, Y. H., Carpenito, C., Wang, G., Surguladze, D., Forest, A., Malabunga, M., Murphy, M. Y., Zhang, Y., Sonyi, A., Chin, D., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0329-7 · Cited by 32
Castella, B., Foglietta, M., Riganti, C., & Massaia, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01492 · Cited by 31
Tan, Z., Liu, L., Chiu, M. S., Cheung, K., Yan, C. W., Yu, Z., Lee, B. K., Liu, W., Man, K., & Chen, Z. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1518672 · Cited by 30
Zhang, L., Li, M., Zhou, Q., Dang, M., Tang, Y., Wang, S., Fu, J., Teng, Z., & Lu, G. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.05.003 · Cited by 30
Metadata
- Authors
- Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S.
- Affiliations
- Inserm (FR)
- Istituto Oncologico Veneto (IT)
- Centre de Recherche Public de la Santé (LU)
- Institut Gustave Roussy (FR)
- University of Verona (IT)
- Unité Institut National de la Santé et de la Recherche Médicale U753, Institut de Cancérologie Gustave Roussy, 94805 Villejuif, France 1
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2014-04-28
- Volume
- 211
- Issue
- 5
- Pages
- 781-790
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC4010891
- OpenAlex
- W2149360266
- Semantic Scholar
- dad078dcb463c50f1571acb3306b01954a153c29
- Cited by
- 2,166
- References
- 24
- Citations by year
- 2026: 171 · 2025: 187 · 2024: 208 · 2023: 219 · 2022: 239 · 2021: 331 · 2020: 224 · 2019: 147 · 2018: 139 · 2017: 120 · 2016: 101 · 2015: 61 · 2014: 18
- FWCI
- 48.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-L1, HIF-1α, hypoxia, myeloid-derived suppressor cells, tumor microenvironment, immune checkpoint blockade, T cell activation, hypoxia response element, IL-10, interleukin-6, tumor-associated macrophages, cancer immunotherapy, CTLA-4, PD-1 ligands
- MeSH terms
- Animals, Diamines, Enzyme-Linked Immunosorbent Assay, Female, Flow Cytometry, Gene Expression Regulation, Luciferases, Lymphocyte Activation, Mice, Inbred C57BL, Organic Chemicals, Quinolines, T-Lymphocytes, Cell Hypoxia, Myeloid Cells, RNA Interference, Chromatin Immunoprecipitation, Mice, Hypoxia-Inducible Factor 1, alpha Subunit, Benzothiazoles, Tumor Microenvironment, Real-Time Polymerase Chain Reaction, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.